Grant: Idea to Innovation
McMaster University
$15,000.00
Proposal for Market Assessment for novel fluorescence-based PoC assay to quantify TXA concentrations in plasma samples
FY 2024-25
Summary
Bleeding disorders may have various causes that affect different pathways of hemostasis - processes in place to stop the blood loss. Regardless of the cause, the phenotype that leads to diagnosis work-up is bleeding events. Furthermore, for disorders of improper clotting (e.g. hemophilia), premature activation of blood clot breakdown (fibrinolysis) may exacerbate the observed bleeding. Taken together, it is evident that pronounced coagulation and sufficient fibrinolysis suppression work in concert for ideal hemostasis. Despite the connection, fibrinolysis in bleeding disorders is still not well understood.
The most common strategy to inhibit fibrinolysis clinically is the use of lysine analogs to prevent activation of fibrinolytic system. Current drug of choice is tranexamic acid (TXA), which is used ubiquitously in bleeding settings such as mild hemophilia, von Willebrand Disease (vWD), rare platelet disorders and trauma. TXA is also used during surgical procedures such as cardiac bypass surgery, in order to prevent excessive bleeding. However, there are no assays available for measuring TXA levels in these patients for ongoing monitoring and care in a hospital setting. Because of the individual nature of TXA administration in these patients, there is no method to prevent overdosing, which could also lead to complications such as seizures. This is particularly of concern in those with kidney dysfunction. Furthermore, children are at risk of TXA overdose since all dosing guidelines are simply based on adult guidelines. Therefore, monitoring TXA levels to ensure therapeutic antifibrinolytic levels are maintained in an individualized manner may lead to enhanced and efficient use of TXA. This could lead to preserved blood product use due to minimal blood loss, as well as reducing the on-going cost of TXA use in women with heavy menstrual bleeding.
We developed a novel, fluorescence based, highly sensitive and specific assay for measuring TXA levels in plasma, with ease of use and rapid data generation (minutes) that is highly attractive for point-of-care testing adaptability.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
592682-2024
Name nom
Kim, Paul Y
Department département
Medicine
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2024
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
9100
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Recherche biomédicale
Research subject fr
Biomedical
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Proposal for Market Assessment for novel fluorescence-based PoC assay to quantify TXA concentrations in plasma samples
Keywords
antifibrinolytics; assay; biochemistry; fibrinolysis; fluorescence; protein protein interaction; surgery; tranexamic acid; trauma
Application summary
Bleeding disorders may have various causes that affect different pathways of hemostasis - processes in place to stop the blood loss. Regardless of the cause, the phenotype that leads to diagnosis work-up is bleeding events. Furthermore, for disorders of improper clotting (e.g. hemophilia), premature activation of blood clot breakdown (fibrinolysis) may exacerbate the observed bleeding. Taken together, it is evident that pronounced coagulation and sufficient fibrinolysis suppression work in concert for ideal hemostasis. Despite the connection, fibrinolysis in bleeding disorders is still not well understood.
The most common strategy to inhibit fibrinolysis clinically is the use of lysine analogs to prevent activation of fibrinolytic system. Current drug of choice is tranexamic acid (TXA), which is used ubiquitously in bleeding settings such as mild hemophilia, von Willebrand Disease (vWD), rare platelet disorders and trauma. TXA is also used during surgical procedures such as cardiac bypass surgery, in order to prevent excessive bleeding. However, there are no assays available for measuring TXA levels in these patients for ongoing monitoring and care in a hospital setting. Because of the individual nature of TXA administration in these patients, there is no method to prevent overdosing, which could also lead to complications such as seizures. This is particularly of concern in those with kidney dysfunction. Furthermore, children are at risk of TXA overdose since all dosing guidelines are simply based on adult guidelines. Therefore, monitoring TXA levels to ensure therapeutic antifibrinolytic levels are maintained in an individualized manner may lead to enhanced and efficient use of TXA. This could lead to preserved blood product use due to minimal blood loss, as well as reducing the on-going cost of TXA use in women with heavy menstrual bleeding.
We developed a novel, fluorescence based, highly sensitive and specific assay for measuring TXA levels in plasma, with ease of use and rapid data generation (minutes) that is highly attractive for point-of-care testing adaptability.